View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
May 15, 2020updated 26 Oct 2021 7:23am

Covid-19 test to detect neutralising antibodies launched

By Chloe Kent

Duke-NUS Medical School, GenScript Biotech Corporation and Singapore’s Agency for Science, Technology and Research (A*STAR) have announced an exclusive agreement to co-develop and manufacture a serological Covid-19 antibody test that allows rapid detection of neutralising antibodies (NAbs).

NAbs are present in the serum of Covid-19 patients and are responsible for clearing the viral infection.

While there are now many Covid-19 antibody test kits available, this is the first that is capable of measuring NAbs, which usually requires the use of live virus cells, highly skilled operators and complex laboratory procedures that are generally less sensitive and require several days to obtain results.

The new test, known as cPass, can be rapidly conducted within an hour in most research or clinical labs.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network